Gout attacks are a diagnostic and prevention problem
For many patients, gout is not a minor inconvenience; it is a sudden, disabling inflammatory arthritis that can mimic infection, fracture, or autoimmune flare. For clinicians, the challenge is deciding when an isolated swollen joint represents crystal disease, when aspiration is necessary, and when long-term urate lowering should begin. The 2020 American College of Rheumatology guideline makes the central point clearly: treating the attack is only one part of care; preventing monosodium urate crystal formation is the strategy that changes the disease course.
Gout matters because it is common, undertreated, and highly preventable. Hyperuricemia is the biochemical substrate, but symptoms occur when urate crystals activate the NLRP3 inflammasome, driving interleukin-1 beta release and an intense neutrophilic response. That mechanism explains why pain peaks quickly and why anti-inflammatory therapy works best early.
Symptoms: why gout feels different
A classic flare begins abruptly, often overnight, with severe pain, warmth, swelling, and erythema in one joint. The first metatarsophalangeal joint, the base of the big toe, is typical, but ankles, knees, wrists, fingers, and elbows are also affected. Skin may look shiny or dusky, and even sheet pressure can be intolerable. Fever and elevated inflammatory markers can occur, which is why septic arthritis remains an important consideration.
An illustrative scenario
Consider a 58-year-old man with hypertension and chronic kidney disease who wakes with a red, swollen knee two days after a holiday meal and several beers. His uric acid was “normal” in the emergency department. That normal value does not exclude gout; serum urate can fall during an acute flare. The clinical pattern raises suspicion, but the swollen knee still deserves careful assessment because infection and crystal arthritis can occasionally coexist.
Triggers are clues, not moral failures
Patients often blame themselves for flares after eating seafood or drinking alcohol. Diet can matter, but gout is not simply a disease of indulgence. Genetics, kidney urate handling, medications, adiposity, and comorbid kidney or cardiovascular disease usually carry more weight than one meal.
Common triggers include:
- Rapid shifts in serum urate, including starting or stopping urate-lowering therapy without prophylaxis
- Alcohol, especially beer and spirits
- High-purine meals, particularly organ meats, some shellfish, and large red-meat portions
- Fructose-sweetened beverages
- Diuretics, low-dose aspirin, cyclosporine, and tacrolimus
- Dehydration, surgery, acute illness, and hospitalization
The misconception is that avoiding purines alone cures gout. In reality, dietary changes usually lower serum urate modestly. They are worthwhile, especially reducing alcohol and sugar-sweetened beverages, but persistent crystal burden generally requires pharmacologic urate lowering when guideline criteria are met.
Diagnosis: prove crystals when the stakes are high
The diagnostic gold standard is identification of negatively birefringent, needle-shaped monosodium urate crystals in synovial fluid under polarized microscopy. Joint aspiration also permits Gram stain and culture, essential when infection is plausible. ACR/EULAR 2015 classification criteria incorporate clinical pattern, serum urate, imaging, and crystal findings, but classification criteria support research consistency; they do not replace bedside diagnostic judgment.
When aspiration is not feasible, ultrasound may show a double-contour sign, reflecting urate on cartilage, and dual-energy CT can identify urate deposits. These tools are helpful, especially in atypical or chronic disease, but false positives and false negatives occur. Serum urate is useful for long-term management, not as a stand-alone test during a flare.
Treating the flare: suppress inflammation early
Acute treatment targets inflammation, not urate concentration. The ACR guideline supports colchicine, nonsteroidal anti-inflammatory drugs, and glucocorticoids as first-line options, chosen according to kidney function, gastrointestinal risk, anticoagulation, diabetes, infection concern, and patient history. Interleukin-1 inhibitors have evidence in selected refractory situations, but access, cost, and infection risk limit routine use.
Timing matters. Low-dose colchicine is most effective when started early and is better tolerated than older high-dose regimens, a finding supported by randomized trial data. Steroid injection can be excellent for a single large joint after infection has been reasonably excluded. Importantly, established urate-lowering therapy is usually continued during a flare; stopping it can amplify urate fluctuation.
Long-term prevention: treat to target, not to symptoms
Gout becomes a chronic disease when urate crystals persist between attacks. The treat-to-target approach, endorsed by the 2020 ACR guideline and consistent with EULAR principles, aims for serum urate below 6 mg/dL for most patients, and often below 5 mg/dL when tophi or severe crystal burden are present. The target matters because crystals dissolve only when body urate stores are sufficiently lowered over time.
Allopurinol is the preferred first-line urate-lowering therapy for most patients, including many with chronic kidney disease, when started low and titrated carefully. Febuxostat is an alternative, with cardiovascular safety interpreted in light of the CARES and FAST trials, which reached different conclusions in different populations. Probenecid can help selected underexcretors but is less useful with reduced kidney function.
Who should be considered for urate-lowering therapy?
- Two or more flares per year
- Tophi on examination or imaging
- Radiographic damage attributable to gout
- Certain first flares with very high urate, kidney stones, or chronic kidney disease, individualized clinically
Prophylaxis with low-dose colchicine, an NSAID, or low-dose prednisone is commonly used during initiation because falling urate mobilizes crystals and can provoke flares. This is not treatment failure; it is biology.
What the evidence supports now
The strongest evidence supports accurate diagnosis, early anti-inflammatory treatment, and sustained urate lowering to a measured target when indicated. Uncertainty remains around optimal imaging use, flare prophylaxis duration, and risk stratification for second-line drugs. The enduring principle is simple: gout attacks are episodic, but crystal disease is longitudinal and clinically preventable.
Medically reviewed by Dr. Adam Elisha, DO, board-certified rheumatologist in Duluth, MN.